| Target Professions: | DO, MD, Nurse, Nurse Practitioner, Physician Assistant |
| Target Specialties: | Hematology, Hematology/Oncology |
| Credits Available: | 4.5 AMA PRA Category 1 Credit™ & 4.5 MOC points |
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries, with an age-adjusted incidence of 4.6 per 100,000 individuals per year. As small lymphocytic lymphoma (SLL) refers to the same malignant process with primary nodal involvement rather than blood, these are generally managed as a single condition (CLL/SLL). The selection of therapies for patients with relapsed/refractory CLL/SLL requires consideration of several factors including previous therapies, disease characteristics, and patient-specific factors such as co-morbidities and concurrent medications. Given the recency of new research into these targeted treatments and new approvals, clinicians lack background knowledge of the most current evidence and guideline recommendations in the treatment of CLL/SLL. Even within national guidelines, specific recommendations for initial treatment choice and sequencing are not directed. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).
The following questions are designed to assess your knowledge and practice of patients with relapsed/refractory CLL/SLL.
This module focuses on providing a comprehensive overview of the current treatment landscape for CLL, highlighting key considerations, and treatment options.
This module focuses on the evidence underlying recently approved and emerging treatments for CLL, both in the front-line and in relapsed/refractory (R/R) settings.
This module focuses on diving deeply into the considerations for treatment sequencing after a patient has become intolerant to treatment or has disease progression.
The following questions are designed to assess your gained knowledge and practice of patients with relapsed/refractory CLL/SLL.
During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).
72yo male with stage 3 CKD & CLL, 13q deletion & mutated IGHV, progresses from watchful waiting to requiring treatment (acalabrutinib). Considerations for new treatment after an adverse event (atrial fibrillation).
66-yr-old with CLL seeks new treatment after disease progression & BTK resistance. Group to explore subsequent line therapy options and selection considerations after disease progression.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL)
During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.
